ClinicalTrials.gg
RecruitingNCT06144671Updated Nov 9, 2026

Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors

A Phase 1/2 interventional study of GT201 and IL-2 in Advanced Solid Tumors, sponsored by Grit Biotechnology. Recruiting at 6 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Grit Biotechnology · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 9, 20265 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a multicenter Phase I/II clinical trial. It aims to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of GT201 in patients with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Grit Biotechnology is the lead sponsor of 30 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Voluntarily enroll in the study, sign the form (ICF), and be willing and able to comply with the study protocol.
  • 2. Aged 18 to 70 years old. For subjects older than 70 years old, eligibility shall be jointly determined by the Investigator and the Sponsor's Medical Monitor.
  • 3. Diagnosis:

    • Phase I trial: Patients with advanced solid tumors who have failed standard therapy, have no available standard therapy, or cannot tolerate standard therapy.
    • Phase II trial: Patients with the target indication who have progressed or are intolerant after receiving the specified treatment outlined in the protocol, and who meet the inclusion and exclusion criteria for the target indication.
  • 4. At least one lesion that is resectable for the preparation of autologous TIL cells.
  • 5. At least one that meets the definition of v1.1 after tumor sampling.
  • 6. (ECOG) performance status of 0 or 1.
  • 7. Estimated survival time ≥ 12 weeks.
  • 8. Functions of major organs meet the requirements specified in the protocol.
  • 9. Female or male subjects of who have not undergone surgical sterilization must agree to use at least one medically acceptable method (e.g., intrauterine device, oral contraceptives, condoms) during study treatment and for 1 year after the end of study treatment. For female subjects of childbearing potential without surgical sterilization, serum human chorionic gonadotropin (hCG) test must be negative within 7 days prior to cell infusion.
  • 10. Prior treatment related adverse events shall have recovered to Grade ≤ 1 per (CTCAE) Version 5.0 before tumor sampling, or be judged by the investigator together with the sponsor's medical monitor not to interfere with the study.
  • 11. For participants enrolled in this study due to disease progression, imaging documentation confirming disease progression following the prior therapy must be available before tumor sampling.

Exclusion criteria

Exclusion Criteria:

  • 1. Patients with spinal cord compression not relieved by surgery and/or radiotherapy are excluded. (Patients may be enrolled if clinical evidence confirms symptom relief for ≥ 1 week prior to tumor harvesting.)
  • 2. Participants with uncontrolled tumor related pain as judged by the investigator. Participants requiring analgesic medications must have a stable analgesic regimen at study entry. Symptomatic lesions suitable for palliative radiotherapy should have completed treatment prior to study entry.
  • 3. Bleeding events within 3 months prior to screening.
  • 4. Patients with arterio-venous thrombotic events that occurred within 6 months prior to screening.
  • 5. Respiratory disorders that severely impair pulmonary function at screening.
  • 6. History of cardiovascular disease, including but not limited to:

    1. Congestive heart failure ( [NYHA] Class >grade II);
    2. Unstable angina pectoris;
    3. Myocardial infarction within the previous 3 months;
    4. Any supraventricular or ventricular arrhythmia requiring treatment or intervention.
  • 7. Participants with ≥ 3 untreated central nervous system (CNS) .
  • 8. Any active disease, history of autoimmune disease, or diseases requiring systemic (>10 mg prednisone daily or equivalent) or agents.
  • 9. Malignant tumors other than the target indication within 5 years.
  • 10. Presence of intractable epilepsy, medically uncontrolled pleural effusion, ascites, pericardial effusion, or any to IL-2 administration.
  • 11. Active infectious diseases within 1 year prior to screening, such as infection, syphilis, active hepatitis, active pulmonary tuberculosis, active Epstein-Barr virus (EBV) and/or cytomegalovirus (CMV) infection; OR history of active pulmonary tuberculosis infection more than 1 year ago without standard treatment; active or .

    • Participants positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) may enroll if HBV DNA level is below the lower limit of quantification (LLOQ) of the local study laboratory.
    • Participants positive for HCV antibody may enroll if HCV RNA level is below the LLOQ of the local study laboratory.
    • Participants with EBV DNA above the laboratory LLOQ may enroll if the Investigator assesses the viremia is tumor-related and the infection is non-active.
    • Carriers enrolled in the study shall receive antiviral therapy at the Investigator's discretion, with regular quantitative nucleic acid testing scheduled throughout the study period.
  • 12. Use of anti angiogenic agents such as bevacizumab within 4 weeks before surgical sampling.
  • 13. Previous bone marrow transplantation or solid organ transplantation.
  • 14. Receipt of systemic anti tumor therapy within 4 weeks prior to lymphodepleting chemotherapy, except for the following:

    • Bridging therapy;
    • If prior chemotherapy with nitrosoureas or mitomycin C was administered, an interval of no less than 6 weeks between the end of such chemotherapy and the anticipated date of lymphodepleting chemotherapy is required for enrolment;
    • If prior small molecule targeted therapy was administered, an interval of no less than 5 half lives of the agent between the end of such therapy and the anticipated date of lymphodepleting chemotherapy is required for enrolment.
  • 15. Prior receipt of genetically modified or gene edited cell therapy products (excluding non genetically modified autologous immune cell therapy products administered more than 1 year before the date of cell infusion).
  • 16. History of reaction to any component of products to be used in the study, including but not limited to autologous TIL, cyclophosphamide, fludarabine, IL-2, dimethyl sulfoxide (DMSO), human serum albumin (HSA), dextran 40, antibiotics (β-lactam antibiotics, gentamicin).
  • 17. Known psychiatric illness, alcoholism, drug addiction or substance abuse.
  • 18. Prior immune therapy related adverse events of Grade 3 or higher that have not recovered to Grade 1 or less within 28 days; or any other disease or medical condition (any other illness, metabolic disorder, physical finding abnormality or laboratory abnormality) that would raise reasonable concerns prohibiting the use of investigational product, confound the interpretation of study results, or place the participant at high risk of treatment related complications.
  • 19. Pregnant or lactating women; or women with plans for pregnancy, conception or lactation within 1 year after the end of study treatment.
  • 20. Receipt of other investigational medicinal products within 4 weeks prior to lymphodepleting chemotherapy, or plan to receive other investigational medicinal products during the study.
  • 21. Other conditions deemed ineligible for enrollment at the investigator's discretion.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    GT201 treatment group

    The treatment groups consist of monotherapy and combination therapy with PD-1. The monotherapy treatment is lymphodepleting chemotherapy followed by infusion of GT201 injection and IL-2. The combination therapy is lymphodepleting chemotherapy followed by infusion of GT201 injection and IL-2, along with continuous administration of PD-1 inhibitor therapy.

    Biological: GT201 · Biological: IL-2 · Biological: PD-1 inhibitor

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Incidence and severity of AEs, SAEs and AE leading to treatment interruption and discontinuation will be graded per NCICTCAE v5.0 (Phase 1)

    Time frame: Up to 2 years

  2. Changes in laboratory parameters

    Evaluate the safety and tolerability based on changes in laboratory parameters before and after treatment. (Phase 1)

    Time frame: Up to 2 years

  3. Objective Response Rate (ORR)

    Proportion of participants achieving a Complete Response (CR) or Partial Response (PR) per RECIST 1.1 (Phase 2).

    Time frame: Up to 2 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    Proportion of participants achieving a Complete Response (CR) or Partial Response (PR) per RECIST 1.1 (Phase 1).

    Time frame: Up to 2 years

  2. Disease control rate (DCR)

    Proportion of participants achieving Complete Response (CR), Partial Response (PR), or Stable Disease (SD) per RECIST 1.1 (Phase 1 and Phase 2).

    Time frame: Up to 2 years

  3. Progression free survival (PFS)

    The time from GT201 infusion to the first documentation of progressive disease (PD) per RECIST 1.1 or death from any cause, whichever occurs first (Phase 1 and Phase 2).

    Time frame: Up to 2 years

  4. Duration of Response (DOR)

    The duration from the first confirmed objective response per RECIST 1.1 to the first documentation of progressive disease (PD) or death from any cause (Phase 1 and Phase 2).

    Time frame: Up to 2 years

  5. Overall survival (OS)

    The time from GT201 infusion to death from any cause (Phase 1 and Phase 2).

    Time frame: Up to 2 years

  6. CD3+ T cell counts

    To evaluate the persistence and expansion of TILs in participants by measuring CD3+ T cell counts in peripheral blood following infusion of GT201 Injection (Phase 1 and Phase 2).

    Time frame: Up to 2 years

  7. GT201 gene copy numbers

    To evaluate the persistence and expansion of TILs in participants by measuring GT201 gene copy numbers in peripheral blood following infusion of GT201 Injection (Phase 1 and Phase 2).

    Time frame: Up to 2 years

  8. Adverse events (AEs)

    Incidence and severity of AEs, SAEs and AE leading to treatment interruption and discontinuation will be graded per NCICTCAE v5.0 (Phase 2)

    Time frame: Up to 2 years

  9. Anti-drug antibodies (ADA)

    Incidence of anti-drug antibodies (ADA) and neutralizing antibodies (Nab) (Phase 1 and Phase 2).

    Time frame: Up to 2 years

07

Study locations

6 of 6 sites recruiting
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Zhiming Li, PHD · Contactlzmlzmlzm@yahoo.com · 13719189172
    • Zhiming Li, PhD · Principal investigator
  • Guangxi Medical University Cancer Hospital
    Nanning, Guangxi 530021, China
    Recruiting
    • Song Qu, PHD · Contact13607887386@126.com · 13607887386
    • Song Qu, PhD · Principal investigator
  • Hunan Cancer Hospital, Xiangya School of Medicine, Central South University
    Changsha, Hunan 410013, China
    Recruiting
    • Yaqian Han, PHD · Contacthanyaqian@hnca.org.cn · 18673176667
    • Yongchang Zhang, PHD · Contactzhanglei1152@126.com · 13873123436
    • Yaqian Han, PhD · Principal investigator
    • Yongchang Zhang, PHD · Principal investigator
  • Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200000, China
    Recruiting
    • Yue He, PhD · Contactwilliam5218@126.com · +86- 13501950200
    • Yue He, PhD · Principal investigator
  • Shanghai General Hospital
    Shanghai, Shanghai Municipality 200080, China
    Recruiting
    • Pin Dong, PHD · Contactdongpin64@aliyun.com · 13764154308
    • Pin Dong, PhD · Principal investigator
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610000, China
    Recruiting
    • Lei Liu, PhD · Contact32498600@qq.com · +86 18980606231
    • Lei Liu, PhD · Principal investigator
    • Li Zheng, PhD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Nov 22, 2023
StartActual
Nov 1, 2025
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 1 site removed
Show 5 added (5 China)
  • Sun Yat-sen University Cancer Center · Guangzhou, China
  • Guangxi Medical University Cancer Hospital · Nanning, China
  • Hunan Cancer Hospital, Xiangya School of Medicine, Central South University · Changsha, China
  • Shanghai General Hospital · Shanghai, China
  • West China Hospital, Sichuan University · Chengdu, China
Show 1 removed
  • West China Hospital Sichuan University · Chengdu, China
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    5 sites added, 1 site removed
    Show 5 added (5 China)
    • Sun Yat-sen University Cancer Center · Guangzhou, China
    • Guangxi Medical University Cancer Hospital · Nanning, China
    • Hunan Cancer Hospital, Xiangya School of Medicine, Central South University · Changsha, China
    • Shanghai General Hospital · Shanghai, China
    • West China Hospital, Sichuan University · Chengdu, China
    Show 1 removed
    • West China Hospital Sichuan University · Chengdu, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06144671
Lead sponsor
Grit Biotechnology
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Nov 1, 2025
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Yue He, PhD
Contact
william5218@126.com
+86- 13501950200

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Tumor Infiltrating Lymphocytes GT201

Start the discussion